Home
button to open the home page
Search Results/
Clinical Outcomes
button to open search results page
Mutations List
button to open mutations list page
Publications
button to open publications page
My Bookmarks
button to open the bookmarks page

Publications

Clinical Trials/Clinical Studies
Collapse Collapse Expand Expand
Compassionate Use Programme/Expanded Access Programme (CUP/EAP)
Collapse Collapse Expand Expand
Case Studies/Case Series
Collapse Collapse Expand Expand
An N et al. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report. Onco Targets Ther. 2019;12:7399-7404.
Cai Y et al. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report. Medicine (Baltimore). 2019;98:e13890.
Caliman E et al. In regard to "Activity of EGFR TKIs in caucasian patients with NSCLC harbouring potentially sensitive uncommon EGFR mutations". Clin Lung Cancer. 2020. [Epub ahead of print].
Chan RT. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival. Asia Pac J Clin Oncol. 2018;(Suppl_1):7-9.
Chen D et al. A novel oncogenic driver in a lung adenocarcinoma patient harboring an EGFR-KDD and response to afatinib. Front Oncol. 2020;10:867.
Chen LC et al. A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor. Respirol Case Rep. 2019;7:e00425.
Chiang C-L et al. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation. J Formos Med Assoc. 2020;119(9):1439-1441. 
Chikamori K et al. Treatment experience of a non-small cell lung cancer (NSCLC) patient harboring EGFR minor mutation L747P where afatinib was effective. Jpn J Lung Cancer. 2016;56:665.
Coupkova H and Vyzula R. Afatinib in the treatment of advanced non-small cell lung cancer with rare EGFR (in exon 18-T179X) mutation - a case report. Klin Onkol. 2018;31:380-383.
Duan H et al. Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report. Onco Targets Ther. 2018;11:2303-2309.
Fang W et al. Acquired EGFR L718V mutation and loss of T790M-mediated resistance to osimertinib in a patient With NSCLC who responded to afatinib. J Thorac Oncol. 2019;14:e274-e275. 
Fang W et al. Durable response of low-dose afatinib plus cetuximab in an adenocarcinoma patient with a novel EGFR exon 20 insertion mutation. J Thorac Oncol. 2019;14:e220-e221.
Fang W et al. Emergence of EGFR G724S after progression on osimertinib responded to afatinib monotherapy. J Thorac Oncol. 2020;15(3):e36-e37. 
Frega S et al. A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib. J Thorac Oncol. 2016;11:e63-e64.
Gallant JN et al. EGFR kinase domain duplication (EGFR-KDD) Is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov. 2015;5:1155-1163.
Galli G et al. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018;115:135-142.
Huang J et al. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib andosimertinib (AZD9291): A case report. Thorac Cancer. 2018;9(6):745-749.
Ibrahim U et al. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. Lung Cancer. 2017;108:45-47.
Iida Y et al. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report. Thorac Cancer. 2019. [Epub ahead of print]. 
Ikeuchi T et al. Successful treatment of lung adenocarcinoma with epidermal growth factor receptor compound mutations involving exon 19 deletion and exon 20 insertion by afatinib. Intern Med. 2019;58:101-104.
Iwamoto Y et al. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. Jpn J Clin Oncol. 2019;pii:hyz086.
Jiang H et al. EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma. Lung Cancer. 2020;145:216-218. 
Kate S et al. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl). 2019;10:1-10.
Kim Y et al. First-line afatinib for non-small cell lung cancer in real-world practice. J Thorac Oncol. 2017;11(Suppl):S2209.
Kimura S et al. Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. Cancer Sci. 2018;109:3657-3661.
Kobayashi Y et al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res. 2015;21:5305-5313.
Kong C et al. Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report. BMC Pulm Med. 2020;20(1):135.
Kunimasa K et al. Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient. Lung Cancer. 2020;148:28-32.
Kutsuzawa N et al. Successful treatment of a patient with lung adenocarcinoma harboring compound EGFR gene mutations, G719X and S768I, with afatinib. Tokai J Exp Clin Med. 2020;45(3):113-116.
Li Y et al. Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib. Transl Lung Cancer Res. 2020;9(5):2188-2190.
Liang SK et al. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019;133:103-109.
Liang SK et al. Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Oncotarget. 2017;8:90430-90443.
Lin L et al. Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations. Onco Targets Ther. 2020;13:9753-9757.
Long X et al. Great efficacy of afatinib in a patient with lung adenocarcinoma harboring EGFR L833V/H835L mutations: A case report. Onco Targets Ther. 2020;13:10689-10692.
Long Y et al. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report. Ann Palliat Med. 2020. [Published online ahead of print.]
Lui J et al. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. BMC Cancer. 2019;19:702. 
Ma C et al. Afatinib for advanced non-small cell lung cancer in a case with an uncommon epidermal growth factor receptor mutation (G719A) identified in the cerebrospinal fluid. Front Oncol. 2019;9:628.
Ma C et al. Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report. Medicine (Baltimore). 2020;99(43):e22851.
Ma C et al. Tyrosine kinase inhibitors could be effective against non-small cell lung cancer brain metastases harboring uncommon EGFR mutations. Front Oncol. 2020;10:224. 
Martin J et al. Clinical impact of rare and compound mutations of epidermal growth factor receptor in patients with non-small-cell lung cancer. Clin Lung Cancer. 2019;pii:S1525-7304(19)30103-2.
Masuda et al. Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and 57681 mutations. Thorac Cancer. 2020.  [Online ahead of print.]
Mehta A et al. Detection of rare targetable EGFR variant in metastatic non-small cell lung carcinoma by next generation sequencing: A case report. Journal of Clinical and Diagnostic Research. 2020;14(6):GD01-GD03.
Moran T et al. Clinical activity of afatinib in patients with non-small cell lung cancer harboring uncommon EGFR mutations: a Spanish retrospective multicenter study. Clin Lung Cancer. 2020;S1525-7304(20)30134-0.
Murano C et al. Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma. EXCLI J. 2019;18:893-898. 
Nakamura T et al. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. PLoS One. 2018;13:e0209384.
Nasu S et al. Osimertinib treatment was unsuccessful for lung adenocarcinoma with G719S, S768I, and T790M mutations. Intern Med. 2018;57(24):3643-3645.
Ning M et al. Afatinib successfully treated leptomeningeal metastasis of lung adenocarcinoma in a patient with EGFR G719A mutation in detection of cerebrospinal fluid. Chinese Journal of Contemporary Neurology and Neurosurgery. 2020;20(6):551-555.
Niogret J et al. Primary resistance to afatinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutations: S768I and V769L. J Thorac Oncol. 2018;13:e113.
Ohara G et al. Long-term survival with afatinib in a patient with lung adenocarcinoma harboring double uncommon EGFR L861Q and G719X mutations. In Vivo. 2020;34(3):1459-1462.
Passaro A et al. Activity of EGFR TKIs in caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations. Clin Lung Cancer. 2019;20:e186-e194.
Patil T et al. Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in Stage IV non–small-cell lung cancer. Clin Lung Cancer. 2020;21(3):e191-e204.
Peled N et al. Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer. J Thorac Oncol. 2017;12:e81-e84.
Puskás R et al. Ritka EGFR mutációt hordozó tüdő adenocarcinomában szenvedő beteg hosszútávú kezelése. Medicina Thoracalis. 2016;69:239-242.
Qin BD et al. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. Onco Targets Ther. 2018;11:4739-4745.
Qin Y et al. Variability of EGFR exon 20 insertions in 24,468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol Oncol. 2020. [Online ahead of print.]
Raez LE et al. EGFR-RAD51 fusion: A targetable partnership originated from the tumor evolution? J Thorac Oncol. 2018;13:e33-e34.
Saxon JA et al. EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib. J Thorac Oncol. 2017;12:884-889.
Sehgal K et al. Clinical benefit of tyrosine kinase inhibitors in advanced lung cancer with EGFR-G719A and other uncommon EGFR mutations. Oncologist. 2020. [Online ahead of print.]
Shen YC et al. Comparing the effects of afatinib with gefitinib or erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer. 2017;110:56-62.
Starrett JH et al. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. Cancer Res. 2020. [Epub ahead of print].
Tamiya M et al. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Invest New Drugs. 2020. [Online ahead of print.]
Tanaka I et al. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung Cancer. 2019;127:169-171.
Urban L et al. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation. Clin Lung Cancer. 2020;S1525-7304(20)30266-7.
van Kempen LC et al. Afatinib in osimertinib-resistant EGFR ex19del/T790M/P794L mutated NSCLC. J Thorac Oncol. 2018;13:e161-e163.
van Veggel B et al. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer. 2020; 141: 9-13.
Wang XF et al. Afatinib achieved remarkable disease control in a Chinese patient with lung adenocarcinoma harboring rare EGFR exon 18-25 kinase domain duplication. Am J Ther. 2019. [Epub ahead of print].
Watanabe M et al. The effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare G719X and S768I mutations. Intern Med. 2018;57:993-996.
Wu SG et al. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol. 2020;12:1758835920946156.
Xu H and Shao C. KIF5B- EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma. Onco Targets Ther. 2020;13:8317-8321.
Yamaguchi T et al. Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. Cancer Treat Commun. 2015;4:169-171.
Yang G et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186-194. 
Yang X et al. Resolving resistance to osimertinib therapy with afatinib in an NSCLC patient with EGFR L718Q mutation. Clin Lung Cancer. 2020;pii:S1525-7304(19)30345-6. 
Zeng L et al. EGFR exon 18 DelE709_T710insD as an acquired resistance mechanism to afatinib in an advanced EGFR exon 18 E709H lung adenocarcinoma. J Thorac Oncol. 2018;13:e93-e95.
Zeng L et al. Identification of a Novel MET Exon 14 skipping variant coexistent with EGFR mutation in lung adenocarcinoma sensitive to combined treatment with afatinib and crizotinib. J Thorac Oncol. 2019;14:e70-e72.
Zhang C et al. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review. Thoracic Cancer. 2020. doi:10.1111/1759-7714.13606
Zhang H et al. Responsiveness to full-dose afatinib in a patient with lung adenocarcinoma harboring EGFR S768I and V769L mutations. J Thorac Oncol. 2019;14(2):e25-e27. 
Zhang X et al. Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR. Lung Cancer. 2020;S0169-5002(20)30512-2.
Zhao Y et. al. Efficacy of osimertinib in afatinib-resistant lung cancer harboring uncommon EGFR mutations: Case report andliterature review. Clinical Lung Cancer. 2020;S1525-7304(20)30211-4.
Zhou T et al. EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report. J Thorac Dis. 2018;10:E802-E805.
Zhu N et al. A patient of advanced NSCLC with a new EGFR Exon 19 insertion mutation and its response to EGFR-TKIs. J Coll Physicians Surg Pak. 2019;29(12):S126-S128.